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Abstract Recent safety issues involving non-active
implantable medical devices (NAIMDs) have highlighted
the need for better pre-market and post-market evaluation.
Some stakeholders have argued that certain features of
medicine safety evaluation should also be applied to
medical devices. Our objectives were to compare the cur-
rent processes and methodologies for the assessment of
NAIMD safety profiles with those for medicines, identify
potential gaps, and make recommendations for the adop-
tion of new methodologies for the ongoing benefit–risk
monitoring of these devices throughout their entire life
cycle. A literature review served to examine the current
tools for the safety evaluation of NAIMDs and those for
medicines. We searched MEDLINE using these two cate-
gories. We supplemented this search with Google searches
using the same key terms used in the MEDLINE search.
Using a comparative approach, we summarized the new
product design, development cycle (preclinical and clinical
phases), and post-market phases for NAIMDs and drugs.
We also evaluated and compared the respective processes
to integrate and assess safety data during the life cycle of
the products, including signal detection, signal manage-
ment, and subsequent potential regulatory actions. The
search identified a gap in NAIMD safety signal generation:
no global program exists that collects and analyzes adverse
events and product quality issues. Data sources in real-
world settings, such as electronic health records, need to be
effectively identified and explored as additional sources of
safety information, particularly in some areas such as the
EU and USA where there are plans to implement the
unique device identifier (UDI). The UDI and other initia-
tives will enable more robust follow-up and assessment of
long-term patient outcomes. The safety evaluation system
for NAIMDs differs in many ways from those for drugs,
but both systems face analogous challenges with respect to
monitoring real-world usage. Certain features of the drug
safety evaluation process could, if adopted and adapted for
NAIMDs, lead to better and more systematic evaluations of
the latter.
Key Points
The collection of safety information and its
integration into the risk management process for
medical devices is not consistent.
Collaboration between all stakeholders is needed to
develop a more proactive safety evaluation process.
This new process should incorporate real-world data
to develop a risk assessment model that is
suitable for all medical devices.
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1 Introduction
Medical devices play an increasingly important role in
healthcare worldwide. A medical device is defined as ‘‘any
instrument, apparatus, appliance, material or other article,
whether used alone or in combination, including the soft-
ware necessary for its proper application intended by the
manufacturer to be used for human beings for the purpose
of diagnosis, prevention, monitoring, treatment or allevia-
tion of disease, replacement or modification of the anatomy
or of a physiological process, and control of conception’’.
Unlike a drug, a medical device does not achieve its
principal intended action in the human body by pharma-
cological, immunological, or metabolic means, but it may
be assisted in its function by such means [1]. Medical
devices are classified into different categories depending
on the risk of harm that comes with their use. The
dimension, complexity, and function of medical devices
vary significantly, ranging from bandages, disposable
gloves, and wheelchairs to more complicated forms such as
active implants (i.e., pacemakers) and computerized sys-
tems used in cataract surgery.
This paper focuses on non-active implantable medical
devices (NAIMDs) and uses these as a proxy to extrapolate
the conclusions of the research, where possible, to other
types of medical devices. An implantable medical device is
one that is partly or totally inserted into the human body or
a natural orifice and expected to stay there for 30 days or
more or that is used to replace an epithelial surface or the
surface of the eye and is expected to stay in use for 30 days
or more. Examples of implantable medical devices include
dental implants, breast implants, hip implants, or intraoc-
ular lenses. Both insertion or application and removal of
implantable medical devices requires surgical or medical
procedures. To be classified as an NAIMD, the medical
device must not have an integral power source [2]. All
NAIMDs fall into the European medical device risk class
IIb and III.
Recent concerns involving NAIMDs, such as the Poly
Implant Prothe`se (PIP) breast implant [3] and the metal-on-
metal hip implant, have shown many questions remain
about the safety and effectiveness of NAIMDs after market
approval, thus highlighting the need for better post-market
monitoring. When compared with medicines, medical
devices pose unique challenges in terms of ensuring their
safe and effective use. Such challenges include user vari-
ability and user learning curves and the technological
complexity or permanent nature of some implants. This
latter challenge is mainly a potential problem with regard
to safety and less with regard to effectiveness. In fact, the
effectiveness of implantable devices is usually higher than
that of drugs because implantable devices, in contrast to
drugs, do not suffer from patient non-adherence.
To address this need for improvement, some stake-
holders have argued that certain features of drug regulation
should be applied to medical devices. This entails the
recommendation or opinion that NAIMDs should undergo
an assessment of their benefit–risk profile prior to being
placed in the market—as well as continuous safety
surveillance monitoring throughout the product life cycle.
However, adoption of the medicinal product benefit–risk
evaluation framework in its entirety may be difficult
because of the significant differences between medicines
and NAIMDs.
For all the reasons mentioned above, worldwide medical
device regulations are undergoing ongoing changes geared
towards improving pre-market and post-market evaluations
of device safety.
In this paper, we compare the processes and method-
ologies used in the assessment of the safety profile of
medical devices with those for medicines to identify
potential gaps and make recommendations for the adoption
of new approaches and methodologies in the medical
device context. To make this comparison more practical,
we used a specific group—NAIMDs, rather than the entire
spectrum of medical devices—as an example.
2 Literature Review Methodology
A literature review served to examine the current tools for
the safety evaluation of NAIMDs and medicines. We
searched MEDLINE using these two categories. We sup-
plemented this search with Google searches using the same
key terms used in the MEDLINE search.
3 Safety Evaluation: A Life Cycle Approach
For both medicines and NAIMDs, the goal is to evaluate
safety throughout the entire life cycle of the product. The
way this is done differs substantially between the two. To
understand the differences between the safety evaluations,
it is important to focus on the different types of adverse
events and to evaluate the factors contributing to these
adverse events. The differences and similarities between
medicines and NAIMDs are shown in Fig. 1.
The design of a NAIMD plays a key role when evalu-
ating possible errors that may arise while using the product.
A study involving healthcare employees from three hos-
pital systems indicated that a lack of training is associated
with most errors. To minimize such errors, user training
should focus on more effective error-prevention strategies
such as retraining of the user during the NAIMD label
review and double checks during critical steps of NAIMD
implantation [4]. The three main causes of adverse events
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have been found to be user challenges, design problems,
and lack of effective training; many of these could be
minimized with adequate training and more user-
friendly medical devices.
For medicines, the factors contributing to adverse events
are mostly pharmacological effect, medication errors, drug
interactions, and incorrect dosing.
These differences in factors contributing to adverse
events influence the safety assessment performed during
development and the post-market phase of a new product.
Some metabolic conditions could contribute to adverse
events for special populations for medicines. For NAIMDs,
other characteristics such as anatomical differences—par-
ticularly in size—need to be considered.
3.1 New Product Development
The pre-market safety assessment for both NAIMDs and
medicines is a process that comprises in-depth planning,
evaluation, and reporting throughout the development of
the product: from discovery and development to preclinical
and clinical testing.
3.1.1 Discovery
The new product development pathway starts with the
discovery phase. For both medicines and NAIMDs, the
time dedicated to new concept and ideation depends on the
level of breakthrough technology of the product, which can
be a very lengthy and complex process.
As an example of breakthrough technology for
NAIMDs, Sir Harold Ridley, inspired by one of his interns,
developed the idea of implanting an intraocular lens (IOL)
and, on 29 November 1949, was the first to successfully do
so [5]. During World War II, Sir Ridley had treated pilots
who had fragments of shattered cockpit in their eyes. He
learned that the acrylic plastic material of the cockpit did
not lead to long-term damage of the eye. Therefore, he
chose the acrylic plastic material for his new invention, the
first IOL. Soon after Sir Ridley’s discovery, several
manufacturers rapidly used his new idea to produce similar
IOLs with improved characteristics.
In 1964, Sir James W. Black developed the first clini-
cally important beta blocker, propranolol, revolutionizing
the medical treatment of angina pectoris [6]. Beta blockers
have been a key contribution to clinical medicine and
pharmacology in the twentieth century. Following Sir
Black’s breakthrough, other beta blockers were developed
as medicines.
Another type of product innovation, also through
breakthrough technology, is the modification of the
structure of existing products. This innovating process is
more rapid for medical devices than for medicines. In
general, modifying the molecular structure of an existing
medicinal product to obtain a new medicinal product
involves a long and protracted process, whereas the
incremental changes made to medical devices can be
released to the market much faster. A new medicinal
product will have to undergo mandatory preclinical and
clinical trials prior to approval and market authorization,
whereas this is not always required to place a device in
the market.
3.1.2 Development
The NAIMD pathway starts with the creation of a new
product. Once the NAIMD has been ideated, the new
prototype enters the iterative development cycle where
continuous amendments and incremental design improve-
ments will be made based on feedback from physicians/
users, technology developments, preclinical testing, man-
ufacturing improvements, and clinical studies. After such
feedback, new ideas are transformed into prototypes, which
are again tested, re-done, optimized, and then finalized.
In contrast, during the discovery of new medicinal
products, many compounds are generated with the objec-
tive of detecting the best candidates for further develop-
ment. The candidate drugs are frequently selected using
in vitro testing models and enter formulation development
in a continuous and unidirectional process.
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3.1.3 Preclinical
After the ideation and development phases, the preclinical
testing starts. For medicines, candidates not excluded in the
initial steps are tested for efficacy and safety in animals.
These animal studies are planned to ascertain a safe dose
with which to start studies in humans, to learn which
organs may be more affected by potential toxic effects, and
to understand pharmacokinetic and dynamic parameters.
Manufacturers of NAIMDs and medicines are required
to test the safety of the new products via ex vivo and
in vivo studies. The role of animal testing for NAIMDs
differs significantly from that of medicines. Contrary to the
process with medicines, where all new products require
organ-specific animal models, the majority of new
NAIMDs do not require animal testing because they often
use materials that are biocompatible with human tissue,
such as stainless steel or ceramic. However, some devices
with novel materials (i.e., materials that have not previ-
ously been used in a marketed medical device with the
same type and duration of contact) might require biocom-
patibility testing in animals [7].
3.1.4 Clinical
Although a large amount of information is obtained from
animal testing, this is not sufficient to rule out human trials.
No animal or in vitro testing is sufficiently comparable to
that in humans; human trials are inevitably required for
medicines. For NAIMDs, clinical trials are used only in
certain circumstances, for example when the biocompati-
bility and safety of NAIMDs cannot be assured during
preclinical trials (both ex vivo and in vivo) (Fig. 2). This is
considered on a product-by-product basis and depends on
the NAIMD materials, components, clinical procedures,
characteristics of the anatomical site for implantation of the
NAIMD, or target populations.
Therefore, for some NAIMDs, unlike for medicines,
extrapolating clinical data from published clinical inves-
tigations or other studies of similar devices in the scien-
tific literature, or from clinical experience of a similar
device may be sufficient to obtain approval to market at
least in most countries. For NAIMDs that require clinical
studies to obtain regulatory approval, the studies are
usually smaller (average number of patients:\500) than
pharmaceutical clinical trials, which are ruled by the size
required to show efficacy [8]. The technical aspects of
medical devices make it difficult to decide how much
clinical data are required for a new NAIMD: substantially
equivalent NAIMDs, and those with a completely new
design or indication will all require different ways of
evaluating NAIMD safety. For NAIMDs, the amount of
clinical data required to obtain the market approval is not
clearly defined.
As can be seen in Fig. 3 [9, 10], safety assessment for
NAIMDs is an iterative process of detecting, assessing,
managing, and communicating the benefits and potential
risks while the product is not yet approved. Although the
pre-market safety assessment for medicines could be iter-










































Fig. 2 Overview of the main differences during new product development between non-active implantable medical devices (NAIMDs) and
medicines
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3.2 Post-Market Surveillance
After the discovery, development, and preclinical and clin-
ical testing phases are successful, the product is licensed for
marketing and enters the post-market phase. Different types
of data related to the actual use of the product are collected,
and these post-market data are integrated into the risk-
management plan (RMP) of the product. The data-collection
processes and the integration of such data are similar but
differ in some aspects between NAIMDs and medicines.
3.2.1 Importance of Data Sources
Data sources are a key aspect in the safety evaluation
process. It is important to consider the different post-
market surveillance data sources and their limitations.
Table 1 provides examples of types of post-market data
sources for both NAIMDs and medicines.
Many data sources are common to both products, but
some have been explored more in one than in the other. For
both NAIMDs and medicines, passive post-market data
sources are easily accessible and well established. On the
other hand, active data sources are further advanced for
medicines than for NAIMDs.
The main differences between NAIMDs and medicines
is that prescription or pharmacy dispensing and electronic
medical records (EMRs) or claims databases for NAIMDs
are underdeveloped. This is primarily because of the lack
of a unique device identifier (UDI). UDIs will enhance
post-market surveillance activities by providing a standard
and unambiguous way to document device use in EMRs or
healthcare utilization databases.
The integration of the UDI into such databases could
potentially support public health-related activities such as
reducing use errors and the reporting and assessing of
adverse events and other problems related to the NAIMD.
It would also enable tracking of product withdrawals,
assessment of patient outcomes and risk–benefit profiles of
NAIMDs across different populations, as well as provide a
viable source of device identification information to the
various stakeholders.
Integrating UDI information into such databases will
increase the use of ‘real-world’ data in the decision-
making process. The US FDA has indicated that estab-
lishing a medical device safety evaluation system to gain
real-world evidence is one of its strategic priorities for
2016–2017. In Europe, on 25 May 2016, an agreement
was reached with the European parliament representa-
tives, and the UDI will become reality in the near future
[11]. This evidence will then aid in the regulatory deci-
sion-making process. The new system aims to lead to a
better and faster identification of safety signals by col-
lecting post-market data in a timely manner. Today’s vast
amount of electronic clinical data will be used to deter-
mine safety signals and support risk–benefit analysis
when the quality of data can be guaranteed and advanced
analytics can be applied [12].
3.2.2 Risk Management
In the life cycle approach, new safety data need to be
included in the RMPs. Again, the general processes are
very similar for medicines and NAIMDs, but some dif-



































Fig. 3 The medicinal product and the non-active implantable medical devices (NAIMDs) development pathway
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3.2.2.1 Adverse Event Coding Worldwide, the accepted
adverse event coding for medicines is that of the Medical
Dictionary for Regulatory Activities (MedDRA). This is
the result of exhaustive work by many stakeholders and a
comprehensive maintenance system by a private company
(Maintenance and Support Services Organization [MSSO])
in charge of ensuring codes reflect changes and innovation
(biologicals and other new products require constant
additions to and refining of the dictionary).
The coding system for adverse events and product
problems for NAIMDs is more heterogeneous than that for
drugs. Different standardized nomenclatures exist for pro-
duct problems (FDA codes and International Organization
for Standardization [ISO] codes) and for patient outcomes
(Systematized Nomenclature of Medicine-Clinical Terms
[SNOMED CT], MedDRA, International Classification
of Diseases [ICD], and FDA Patient Problem Codes). As
seen in Table 3 [13–16], the standardized nomenclature
systems vary significantly with regards to number of terms,
granularity, hierarchy, and availability in different
languages.
3.2.2.2 Signal Management Process The aim of signal
detection for both medicines and NAIMDs is to promptly
identify risks associated with the use of a product [17].
Decisions as to whether a finding represents a ‘safety sig-
nal’ and whether it warrants further investigation can be
challenging.
Table 1 Examples of post-market data sources for non-active implantable medical devices and medicines
NAIMDs Medicines
Spontaneous Reports MAUDE (FDA), MEDSUN (FDA),
MHRA (UK)
AERS (FDA), EudraVigilance (EEA),
VigiBase (WHO)
Patient Registries SCAAR, EUREQUO, AOANJRR ESID, Atassia Teleangiectasia (Italy)
Prescription Databases Underdeveloped The Intensive Medicines Monitoring Programme
(New Zealand), NorPD
Claims Data Sources Medicare & Medicaid (USA) FDA Sentinel, Medicare & Medicaid (USA)
EMR Databases Underdeveloped EUADR, FDA Minisentinel,
General Practice Research Database (UK)
Public Information on Safety Issues Medical Device Safety (FDA),
Catalan Agency for Health Technology
Assessment and Research
CDER (FDA), PRAC (EMA)
Post-Authorization Studies Post-market clinical follow-up studies (EU),
post-approval studies (USA), 522 Studies (USA)
Interventional study (efficacy study, PASS, PAS)
and non-interventional study (efficacy study,
PASS, PAS)
AERS Adverse Event Reporting System, AOANJRR Australian Orthopaedic Association National Joint Replacement Registry, CDER Center for
Drug Evaluation and Research, EEA European Economic Area, EMA European Medicines Agency, EMR electronic medical records, ESID
European Society of Immunodeficiencies, EUADR Exploring and Understanding Adverse Drug Reactions, EUREQUO European Registry of
Quality Outcomes for Cataract and Refractive Surgery, FDA US Food and Drug Administration,MAUDEManufacturer and User Facility Device
Experience, MedSun Medical Product Safety Network, MHRA Medicines and Healthcare products Regulatory Agency, NAIMD non-active
implantable medical devices, NorPD Norwegian Prescription Database, PAS post-authorization study, PASS post-authorization safety study,
PRAC Pharmacovigilance Risk Assessment Committee, SCAAR Swedish Coronary Angiography and Angioplasty Registry, WHO World Health
Organization
Table 2 Risk management processes for non-active implantable medical devices and medicines
NAIMDs Medicines
AE Coding Product problem: FDA and ISO
Patient Outcome: SNOMED, MedDRA, ICD, FDA
MedDRA
Signal management process Signal detection, signal validation, signal prioritization,
signal escalation, regulatory actions and connections
with other processes not as clearly regulated
Signal detection, signal validation, signal
prioritization, signal escalation, regulatory
actions clearly regulated
Benefit–risk analysis Underdeveloped, RMF PSURs/PBRERs, RMPs
Regulatory actions Withdrawal, Recall, Restriction, Ban, DFU update,
Dear Doctor Letter (USA), Field Safety Notice (EU)
Withdrawal, SmPC update, black box
warning, Dear Doctor Letter
AE adverse event, DFU directions for use, FDA US Food and Drug Administration, ICD International Classification of Diseases, ISO Inter-
national Organization for Standardization, MedDRA Medical Dictionary for Regulatory Activities, PBRER periodic benefit–risk evaluation
reports, PSUR periodic safety update reports, RMF risk management file, RMP risk management plan, SmPC Summary of Product Charac-
teristics, SNOMED Systematized Nomenclature of Medicine
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Quantitative signal detection is followed by a signal vali-
dation process that confirms whether or not the signal is real
(Fig. 4). This is often verified through qualitative analysis of
case evaluation. Thereafter, the signal is prioritized on the basis
of the strength of the signal,whether or not the signal represents
a new finding, the clinical importance and potential public
health implications of the issue, and the potential for preventive
measures to mitigate the adverse public health impact.
After signal prioritization, the manufacturer or market-
ing authorization holder decides whether or not the signal
must be escalated and whether or not any regulatory
actions should be taken as risk minimization measures to
address the safety issue [17].
Although the signal management process is the same,
the legislation requirements are better described in phar-
maceutical regulations [18–20]. This is not the case for
NAIMDs; guidelines giving practical advice on signal
management are yet to be developed. Drug regulations
were developed earlier than medical device regulations,
which explains and results in the poor description of leg-
islation requirements for medical devices.
For medicines, new pharmacovigilance regulations in
the EU have highlighted the relevance of signal manage-
ment, and the European Medicines Agency’s recently
established Pharmacovigilance Risk Assessment Commit-
tee (PRAC) has been instructed to supervise all aspects of
the use of medicines, including signal management and
prioritization [21]. Numerous worldwide initiatives are
investigating new methods to facilitate earlier signal
detection, mainly through mining of routinely collected
data from electronic healthcare records (EHRs) [22].
3.2.2.3 Post-Market Benefit–Risk Analysis Post-market
benefit–risk analysis can be defined as a comparative
assessment of benefits (positive effects) and risks (potential
harms) of a particular product (medicinal product or
medical device) after it has been introduced to the market.
This is an iterative and dynamic process comprising four
phases (Fig. 5). In the first stage, the benefits and risks
should be defined. Thereafter, activities aimed at benefit
optimization and risk mitigation or minimization should be
outlined. During the third stage, the product should be
assessed on the basis of its effectiveness and safety
throughout its entire life cycle. In the fourth stage, the RMP
should be revised if the benefit–risk profile of the product
has changed.
The process is the same for both NAIMDs and medi-
cines. However, the requirements for a benefit–risk anal-
ysis framework are more defined for medicines because of
Table 3 Standardized nomenclature for describing patient outcomes
MedDRA SNOMED CT ICD US FDA patient
problem codes
Number of terms 70,000 311,000 70,000 700
Hierarchy High Medium Medium Low
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Fig. 4 Signal management process for both non-active
implantable medical devices (NAIMDs) and medicines
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the more developed legislation. For medicines, there is a
regulatory requirement to submit periodic safety update
reports (PSURs)/periodic benefit–risk evaluation reports
(PBRERs). PSURs/PBRERs are pharmacovigilance docu-
ments intended to provide an evaluation of the benefit–risk
balance of a medicinal product. These reports are submit-
ted by marketing authorization holders at defined time
points during the post-authorization phase [23]. PSURs/
PBRERS are not currently required for NAIMDs.
In terms of risk-management document submission,
there is a regulatory requirement for both medicines and
NAIMDs: updated RMPs for medicines [24] and updated
risk-management files (RMFs) for NAIMDs [25].
3.2.2.4 Regulatory Actions Regulatory actions are well
defined for both types of products. However, what constitutes
a regulatory action differs, often by country or region, and
there is no harmonization across jurisdictions. Moreover, the
regulatory approval process for medical devices also differs
widely across jurisdictions. For example, in the USA, the
FDA approves the marketing of a new medical device and
has tools to restrict the use of or ban a device and remove
unsafe products from the market [17]. Conversely, in Europe,
the pre-market evaluation of a device is performed by the
notified body, which includes the assessment and verification
of the clinical evaluation. Once medical devices bear the CE
marking, they can circulate freely within the EU. In the post-
market environment, it is sometimes difficult for the EU
Member States to stop production, CE labelling, or distri-
bution of medical devices [26]. Medical devices marketed
first in the EU have a higher risk of post-marketing safety
issues than medical devices first marketed in the USA [27].
4 Discussion
4.1 Role of the Patient
The patient needs to be aware of potential risks and able to
easily communicate their personal experience relating to
the safety and effectiveness of the device. Patient associ-
ations should be involved in defining the new regulations
and guidelines for safety evaluation systems for medical
devices.
Some initiatives have already been undertaken to try to
develop a systematic methodology to calculate and
include patient information into the medical device safety
evaluation system [28] and encourage patient engagement
[29]. The goal should be to obtain a more patient-centric
system. The patient should be a key stakeholder in public
health.
4.2 Recommendations
The basic systems for safety evaluation of medical devices
and medicines are not very different from a conceptual
perspective; however, gaps currently exist in the safety
evaluation of medical devices. This paper has identified
these gaps, and some recommendations on how to fill these
gaps follow.
As seen in Fig. 6, the recommendations are ordered in
three categories: harmonization and centralization, safety
evaluation tools, and user training and customer service.
4.2.1 Harmonization and Centralization
Adverse event coding should be harmonized to improve the
signal detection process. It is recommended that a global
and centralized database, such as the World Health Orga-
nization (WHO) Vigibase, be established for the assembly
of all medical device reports.
Moreover, a worldwide evaluation system should be
developed for medical devices and should include repre-
sentatives from the different stakeholders [12]. This sys-
tem also does not yet exist for medicines and could use
real-world evidence to support regulatory decision mak-
ing. To ensure successful implementation of this system,
three steps need to be incorporated: (1) the UDIs need to
be consistently assembled within electronic health infor-
mation, (2) all stakeholders need to ensure a continual use
of the EHRs, including UDIs, and lastly (3) to link patient
data, all data sources need to have interoperable linking
capabilities [30]. This is a long-term goal because it
involves policy change. Therefore, these three steps could
take years or even decades.
For these harmonization and centralization recommen-
dations to succeed, there must be active collaboration and
support from all stakeholders.
Further to the recommendations listed above, there must
be regulatory methodology harmonization: the regulatory
approval process and the definitions of regulatory actions
need to be aligned across jurisdictions to enable a more
robust signal management process.
Review RMP if 
benefit-risk profile changes






Fig. 5 Post-market benefit-risk analysis for both non-active
implantable medical devices (NAIMDs) and medicines. RMP
risk management plan
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4.2.2 Safety Evaluation Tools
Post-market surveillance data are very important for med-
ical devices because they provide valuable information
regarding user variability. Relevant authorities could make
more safety evaluation tools available to the different
stakeholders to improve safety assessment:
1. Regulatory documents providing further guidance on
the different steps in the signal management process.
For instance, the following signal detection guidance
has already been established for medicines: the report
of the Council for International Organizations of
Medical Sciences (CIOMS) Working Group VIII and
the guidelines on good pharmacovigilance practices
(GVP) module IX—signal management [19, 20].
2. A post-market surveillance (PMS) plan should be
submitted for every medical device or group of
medical devices to serve as a summary of all collected
post-market information and as a guide to utilizing
such information [2].
3. A post-market clinical follow-up study plan should
also be part of the PMS plan [2].
4. PSURs for every medical device or group of medical
devices to reinforce the benefit–risk analysis process.
5. The clinical data required (from both a quantitative
and a qualitative perspective) to obtain the market
approval should be defined in guidelines and should be
consistent with the risk associated with the product
and/or how innovative the device is. Medical devices
with a high level of innovation (new material, new
product, new surgical procedure) and/or a high level of
risk should require more clinical data. For these types
of products, more evidence should be generated during
the pre-market phase to better define expected risks.
Single-blind randomized controlled trials (RCTs) with
these types of implantable medical devices should be
conducted when required and if possible. Previous
experience with similar devices should also be con-
sidered as evidence when deciding the clinical data
required.
4.2.3 User Training and Customer Service
As previously stated (Fig. 1), user error and the user’s
learning curve are two vital factors contributing to adverse
events with medical devices. Manufacturers should pri-
marily focus on user training as the most important
risk minimization tool. Proper training should be provided
to reduce user variability. Providing excellent customer
service to the medical device user will supply the manu-
facturer with substantial knowledge about the medical
device safety profile. To guarantee outstanding customer
service, training standards need to be implemented to




User training and 
customer service
• Coding harmonization to improve the signal detection (ISO, 
FDA)
• Partnerships to build a worldwide system for medical 
devices in order to integrate all type of post-market data 
sources 
• Global centralized database  for collection of reports related 
to medical devices
• Harmonization of regulatory actions across jurisdictions
• New benefit-risk evaluation tools: PMS Plan and PSURs
• More post authorization studies developed and performed in 
order to address safety concerns
• Robust signal management process for medical devices 
(CIOMS VIII)
• The clinical data required to obtain the market approval 
should be defined in guidelines
• User training as the most important risk minimization 
measure
• Provide excellence customer service to the medical device 
user 
Fig. 6 Recommendations to cover gaps in the safety evaluation of
medical devices. CIOMS Council for International Organizations of
Medical Sciences, FDA US Food and Drug Administration, ISO
International Organization for Standardization, PMS post-market
surveillance, PSUR periodic safety update reports
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members need to be trained on these standards and briefed
about the company’s vision on customer service. To
measure the efforts of staff and to evaluate the success of
the training, a framework should be designed to measure
quality and its consistency. Lastly, the company can only
learn and grow from opinions and feedback from their
customers. This should be received through customer sur-
veys, which should be shared with the team and made
public to all stakeholders [12].
5 Conclusions
Traditionally, the collection of safety information and its
integration into the risk management process of medical
devices has been neither consistent nor performed for all
products.
To address this weakness, health authorities have started
to work on new regulatory documents. Patients must be the
key pillars and public health the cornerstone of this new
system. Now is the time for collaboration between all
stakeholders to develop a more proactive safety evaluation
process. This new process should incorporate real-world
data to develop a risk assessment model that is suitable for
all medical devices.
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